Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study

Table 3 Association of SRF and two-grade macular HEs aggravation at one month in both groups

	Disease	n	HEs aggravation eyes	HEs non-aggravation eyes	P-*value*
CME without SRF	DR	69	17 (24.6%)	52 (75.3%)	0.087
CME without SRF	BRVO	78	10 (12.8%)	68 (87.1%)	0.087
CME with SRF	DR	77	34 (44.1%)	43 (55.8%)	0.010*
CME with SRF	BRVO	64	15 (23.4%)	49 (76.5%)	0.010*
Total	–	288	76 (26.3%)	212 (73.7%)
CME without SRF	–	147	27 (18.3%)	120 (81.6%)	0.001*
CME with SRF	–	141	49 (34.7%)	92 (65.2%)	0.001*

HE Hard exudate, CME Cystoid macular edema, SRF Subretinal fluid. *, p < 0.05 by chi-square test

ISSN: 1471-2415